Evidence map›Paper›PMID 42780675›Full record

ArticleActa Cardiologica Sinica2026

Long-Term Impact of Eplontersen on Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Ala97Ser Hereditary Transthyretin Amyloid Cardiomyopathy.

Yi-Hsin Hung, An-Li Yu, Min-Jhih Chen, Cheng-Hsuan Tsai, Yi-Chieh Chen, Chi-Chao Chao, Mao-Yuan Su, Hsueh-Wen Hsueh, Ming-Jen Lee, Ping-Huei Tseng and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta Cardiologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yi-Hsin HungDepartment of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine.
An-Li YuDepartment of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine.
Min-Jhih ChenDepartment of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine.
Cheng-Hsuan TsaiDepartment of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine.
Yi-Chieh ChenDepartment of Nuclear Medicine.
Chi-Chao ChaoDepartment of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine.
Mao-Yuan SuDepartment of Medical Imaging, National Taiwan University Hospital, Taipei.
Hsueh-Wen HsuehDepartment of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine.
Ming-Jen LeeDepartment of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine.
Ping-Huei TsengDepartment of Internal Medicine, Division of Gastroenterology, National Taiwan University Hospital and National Taiwan University College of Medicine.
Wei-Chou LinDepartment of Forensic Medicine and Pathology, National Taiwan University Hospital.
Wei-Chen LinDepartment of Forensic Medicine and Pathology, National Taiwan University Hospital.
Sung-Tsang HsiehDepartment of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine.
Mei-Fang ChengDepartment of Nuclear Medicine.
Yen-Hung LinDepartment of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive disease. Emerging evidence supports bone scintigraphy as a noninvasive tool for monitoring treatment response. We aimed to evaluate the long-term impact of eplontersen therapy on technetium-99m pyrophosphate ( Methods: We retrospectively analyzed data from a prospective cohort enrolled in the NEURO-TTRansform trial, including hATTR-CM patients treated with eplontersen. Patients who underwent baseline and at least two post-treatment Results: Five patients met the inclusion criteria. The mean follow-up durations were 22.4 months (first follow-up) and 37.5 months (second follow-up). A significant reduction in the volumetric heart-to-lung ratio was observed from baseline to first follow-up (3.75 ± 0.53 to 2.94 ± 0.38, p = 0.010) and to second follow-up (3.75 ± 0.53 to 2.86 ± 0.39, p = 0.009). A further reduction between the first and second follow-up was also noted (2.94 ± 0.38 to 2.86 ± 0.39, p = 0.025). Conclusions: Serial

Indexed as

99mTc-pyrophosphate single-photon emission computed tomography/computed tomographyEplontersenTransthyretin amyloid cardiomyopathy

Identifiers

PMID42780675
PMCPMC13598604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.